Does Rallies show Form 4 insider transactions for BMRA?

Yes. Rallies tracks BMRA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is BMRA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BMRA. It does not provide personalized investment advice.

BMRA (BIOMERICA INC) Stock Analysis - Insider Trades

BIOMERICA INC (BMRA) is a publicly traded Healthcare sector company. As of May 21, 2026, BMRA trades at $2.35 with a market cap of $6.95M and a P/E ratio of -0.93. BMRA moved +0.00% today. Year to date, BMRA is -9.62%; over the trailing twelve months it is -35.44%. Its 52-week range spans $1.87 to $10.16. Rallies surfaces BMRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading BMRA stock inside the company?

Recent BMRA insider activity includes Irani Zackary S. bought 200, Irani Zackary S. bought 500, Irani Zackary S. bought 1.70K, Irani Zackary S. bought 500, and Irani Zackary S. bought 300. Rallies tracks insider transaction dates, shares, prices, and estimated values.

BMRA Key Metrics

Key financial metrics for BMRA
Metric	Value
Price	$2.35
Market Cap	$6.95M
P/E Ratio	-0.93
EPS	$-2.49
Dividend Yield	0.00%
52-Week High	$10.16
52-Week Low	$1.87
Volume	1
Avg Volume	0
Revenue (TTM)	$4.46M
Net Income	$-4.03M
Gross Margin	5.61%

Recent BMRA Insider Trades

Irani Zackary S. bought 200 (~$310) on May 25, 2023.
Irani Zackary S. bought 500 (~$805) on May 24, 2023.
Irani Zackary S. bought 1.70K (~$1.99K) on May 12, 2023.
Irani Zackary S. bought 500 (~$635) on May 10, 2023.
Irani Zackary S. bought 300 (~$417) on May 9, 2023.

Latest BMRA News

Biomerica to Present Real-World inFoods IBS Study Showing 59.6% Pain Reduction — Apr 29, 2026
Biomerica Opens Medicare Claims Pathway for inFoods IBS with $300 Reimbursement Rate — Apr 16, 2026
Biomerica Launches inFoods IBS in Canada Targeting 5M Patients with 18% Prevalence — Apr 14, 2026
Biomerica Secures $300 Medicare Reimbursement, Reports 45% European Revenue Growth — Apr 13, 2026
Biomerica Secures First UK Order for MHRA-Approved Hp Detect™ from Top European Lab Chain — Mar 18, 2026

BMRA Analyst Consensus

BMRA analyst coverage data. Average price target: $0.00.

Common questions about BMRA

Who is trading BMRA stock inside the company?: Recent BMRA insider activity includes Irani Zackary S. bought 200, Irani Zackary S. bought 500, Irani Zackary S. bought 1.70K, Irani Zackary S. bought 500, and Irani Zackary S. bought 300. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for BMRA?: Yes. Rallies tracks BMRA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is BMRA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BMRA. It does not provide personalized investment advice.